ScreenPoint Medical, a global leader in AI-powered breast imaging solutions, has announced the acquisition of Biomediq A/S, a Danish company specializing in quantitative imaging biomarkers. The strategic move strengthens ScreenPoint’s risk assessment capabilities within its flagship Breast AI platform, Transpara®, following more than a decade of close collaboration between the two companies.
Biomediq’s mammographic texture risk model—an AI-based biomarker that analyzes tissue heterogeneity in 2D and 3D mammograms—will be integrated into Transpara to provide enhanced prediction of both short- and long-term breast cancer risk. This addition complements Transpara’s existing CE-marked and FDA-cleared capabilities, including detection, breast density, and temporal comparison.
"We are excited to add the Biomediq risk analysis technology to enhance the capabilities of Transpara to improve performance for mammography-based breast cancer risk assessment. This is a game-changing step in providing accurate and consistent breast cancer detection and care for all women."– Professor Nico Karssemeijer, co-founder and Chief Scientific Officer of ScreenPoint Medical
A 2023 Radiology study demonstrated the clinical potential of combining Transpara’s lesion detection and density tools with Biomediq’s texture analysis, resulting in improved risk prediction and the opportunity for earlier diagnosis of interval cancers. The study’s lead author, Dr. Andreas D. Lauritzen, will join ScreenPoint to accelerate further development of Transpara’s risk capabilities.
Professor Mads Nielsen, co-founder of Biomediq, will remain an advisor to ScreenPoint, supporting the integration and future innovation. With more than 35 peer-reviewed publications and validation across leading institutions worldwide, Transpara remains the most clinically validated Breast AI platform on the market.
